pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM
Mirum Pharmaceuticals International
Mirum Pharmaceuticals International B.V.
Mirum Pharmaceuticals International is a pharma organization headquartered in Foster City, USA. It trades on NYSE under ticker MIRM. Primary therapeutic focus areas include Alagille Syndrome, Progressive Familial Intrahe
Company details
- Status
- Public
- HQ
- 989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
- Founded
- 2018
- Employees
- 436
- Programs
- 25
- Drugs
- 10
- Patents
- 4
Quick answer
Mirum Pharmaceuticals International is a pharma organization headquartered in Foster City, USA. It trades on NYSE under ticker MIRM. Primary therapeutic focus areas include Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis (PFIC), Intrahepatic Cholestasis of Pregnancy, Chronic Hepatitis D Infection, Chronic Hepatitis D. NovaPharmaNews links 25 clinical program(s), 3 drug profile(s), and 4 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (15), phase 3 (8), approved (1).
Company snapshot
Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixib
- 5 approved product(s) across US/EU regulatory metadata.
- 25 active pipeline program(s) linked via ClinicalTrials.gov.
- 4 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Mirum Pharmaceuticals International. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Recent coverage
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Mirum Pharmaceuticals International.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Mirum Pharmaceuticals International.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Mirum Pharmaceuticals International?
-
Is Mirum Pharmaceuticals International publicly traded?
-
What drugs does Mirum Pharmaceuticals International develop or market?
-
What are the latest developments for Mirum Pharmaceuticals International?
-
What therapeutic areas does Mirum Pharmaceuticals International focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.